Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 09/30/13 → 06/25/15 |
Funding
- National Cancer Institute: $6,350.00
A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer Who Have Residual Tumor ....
- Cohen, Jules A (CoPI)
- Kudelka, Andrzej (PI)
- Lu, Janice (PI)
- O'Hea, Brian (CoPI)
- Rizk, Christine (CoPI)
Project: Research